Scholarlink

Background <p>Interleukin-39 (IL-39) is a cytokine implicated in immune regulation and autoimmune diseases, but its role in myasthenia gravis (MG) is unknown. This study aimed to investigate serum IL-39 levels in MG patients.</p> Methods <p>Serum IL-39 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 51 acetylcholine receptor (AChR) antibody-positive MG patients without thymoma and 43 healthy controls (HCs). A subset of 20 patients who achieved sustained clinical remission after heterogeneous immunotherapy provided paired samples for longitudinal analysis.</p> Results <p>Serum IL-39 levels were significantly higher in active MG patients compared to HCs [median: 5.09&#xa0;pg/mL (IQR: 4.12–6.23) vs 1.83&#xa0;pg/mL (IQR: 0.99–2.76); <i>p</i> &lt; 0.001]. In the paired analysis, IL-39 levels were significantly lower during the remission phase than at the active disease baseline [median: 1.66&#xa0;pg/mL (IQR: 0.94 ~ 3.31) vs 4.28&#xa0;pg/mL (IQR: 3.69 ~ 5.33); <i>p</i> &lt; 0.001]. IL-39 demonstrated high discriminatory capacity between active patients and HCs (AUC = 0.922). No correlation was found between baseline IL-39 levels and clinical severity scores (MG-ADL).</p> Conclusion <p>Serum IL-39 levels are dynamically associated with disease activity states in AChR + MG, decreasing with clinical remission. Its lack of correlation with symptom severity and its likely non-specific nature suggest it may serve as a marker of general immune activation rather than a specific diagnostic or severity biomarker. Further studies are needed to validate its specificity and define its role in MG immunopathology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elevated serum Interleukin-39 in Myasthenia gravis: a possible biomarker

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Kun Jia,
  • Yingzhe Shao,
  • Xuan Liu,
  • Qiuxia Zhang,
  • Li Yang

摘要

Background

Interleukin-39 (IL-39) is a cytokine implicated in immune regulation and autoimmune diseases, but its role in myasthenia gravis (MG) is unknown. This study aimed to investigate serum IL-39 levels in MG patients.

Methods

Serum IL-39 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 51 acetylcholine receptor (AChR) antibody-positive MG patients without thymoma and 43 healthy controls (HCs). A subset of 20 patients who achieved sustained clinical remission after heterogeneous immunotherapy provided paired samples for longitudinal analysis.

Results

Serum IL-39 levels were significantly higher in active MG patients compared to HCs [median: 5.09 pg/mL (IQR: 4.12–6.23) vs 1.83 pg/mL (IQR: 0.99–2.76); p < 0.001]. In the paired analysis, IL-39 levels were significantly lower during the remission phase than at the active disease baseline [median: 1.66 pg/mL (IQR: 0.94 ~ 3.31) vs 4.28 pg/mL (IQR: 3.69 ~ 5.33); p < 0.001]. IL-39 demonstrated high discriminatory capacity between active patients and HCs (AUC = 0.922). No correlation was found between baseline IL-39 levels and clinical severity scores (MG-ADL).

Conclusion

Serum IL-39 levels are dynamically associated with disease activity states in AChR + MG, decreasing with clinical remission. Its lack of correlation with symptom severity and its likely non-specific nature suggest it may serve as a marker of general immune activation rather than a specific diagnostic or severity biomarker. Further studies are needed to validate its specificity and define its role in MG immunopathology.